Expression of xCT as a predictor of disease recurrence in patients with colorectal cancer

Anticancer Research

Volumn 35, Issue 2, 2015, Pages 677-682

  Sugano, Kenji ^a   Maeda, Kiyoshi ^a   Ohtani, Hiroshi ^a   Nagahara, Hisashi ^a   Shibutani, Masatsune ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CD44v6; Colorectal cancer; CRC; Immunohistochemistry; Recurrence; xCT

Indexed keywords

CD44V6 ANTIGEN; CYSTEINE; GLUTAMIC ACID; HERMES ANTIGEN; TUMOR MARKER;

AGED; COLORECTAL TUMOR; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; RISK FACTOR;

AGED; ANTIGENS, CD44; COLORECTAL NEOPLASMS; CYSTEINE; FEMALE; GLUTAMIC ACID; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84923666783     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Boyle P and Ferlay J: Cancer incidence and mortality in Europe. Ann Oncol 16: 481-488, 2005.
2. World Cancer Research Fund and American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: American Institute for Cancer Research, 2007,
3. Langan RC, Mullinax JE, Ray S, Raiji MT, Schaub N, Xin HW, Koizumi T, Steinberg SM, Anderson A, Wiegand G, Butcher D, Anver M, Bilchik AJ, Stojadinovic A, Rudloff U and Avital I: A pilot study assessing the potential role of non-CD133 colorectal cancer stem cells as biomarkers. J Cancer 3: 231-240, 2012.
4. Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J Jr, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP and Willett C: NCCN clinical practice guidelines in oncology : colon cancer. J Natl Compr Canc Netw 7: 778-831, 2009.
5. Lo M, Wang Y and Gout P: The xc cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases. J Cell Physiol 215: 593-602, 2008.
6. Backos DS, Franklin CC and Reigan P: The role of glutathione in brain tumor drug resistance. Biochem Pharmacol 83: 1005-1012, 2012.
7. Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, Matzku S, Wenzel A, Ponta H and Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65: 13-24,1991.
8. Nagano O and Saya H: Mechanism and biological significance of CD44 cleavage. Cancer Sci 95: 930-5, 2004.
9. Ponta H, Sherman L and Herrlich PA: CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4: 33-45, 2003.
10. Nagano O, Okazaki S and Saya H: Redox regulation in stemlike cancer cells by CD44 variant isoforms. Oncogene 32: 5191-5198, 2012.
11. Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S, Cocorullo G, Gulotta G, Dieli F, De Maria R and Stassi G: CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 14: 342-456, 2014.
12. Ishimoto T, Nagano O and Yae T: CD44 Variant regulates redox status in cancer cells by stabilizing the xCT Subunit of system xc and thereby promotes tumor growth. Cancer Cell 19: 387-400, 2011.
13. Yoshikawa M, Tsuchihashi K, Ishimoto T, Yae T, Motohara T, Sugihara E, Onishi N, Masuko T, Yoshizawa K, Kawashiri S, Mukai M, Asoda S, Kawana H, Nakagawa T, Saya H and Nagano O: xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res 73: 1855-1866, 2013.
14. Takeuchi S, Wada K, Toyooka T, Shinomiya N, Shimazaki H, Nakanishi K, Nagatani K, Otani N, Osada H, Uozumi Y, Matsuo H and Nawashiro H: Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas. Neurosurgery 72: 33-41, 2013.
15. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padró M, Daemen A, Hu M, Chan DA, Ethier SP, van't Veer LJ, Polyak K, McCormick F and Gray JW: Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 24: 450-465, 2013.
16. Kinoshita H, Okabe H, Beppu T, Chikamoto A, Hayashi H, Imai K, Mima K, Nakagawa S, Ishimoto T, Miyake K, Yokoyama N, Ishiko T and Baba H: Cystine/glutamic acid transporter is a novel marker for predicting poor survival in patients with hepatocellular carcinoma. Oncol Rep 29: 685-689, 2013.
17. Shiozaki A, Iitaka D, Ichikawa D, Nakashima S, Fujiwara H, Okamoto K, Kubota T, Komatsu S, Kosuga T, Takeshita H, Shimizu H, Nako Y, Sasagawa H, Kishimoto M and Otsuji E: xCT, component of cysteine/glutamate transporter, as an independent prognostic factor in human esophageal squamous cell carcinoma. J Gastroenterol 49: 853-863, 2014.
18. Sobin LH, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant Tumours (ed 7). Weinheim, Germany, Wiley, 2009,
19. Saito S, Okabe H, Watanabe M, Ishimoto T, Iwatsuki M, Baba Y, Tanaka Y, Kurashige J, Miyamoto Y and Baba H: CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer. Oncol Rep 29: 1570-1578, 2013.
20. Jung T, Gross W and Zöller M: CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance. J Biol Chem 286: 15862-15874, 2011.
21. Mulder JW, Kruyt PM, Sewnath M, Oosting J, Seldenrijk CA, Weidema WF, Offerhaus GJ and Pals ST: Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 344: 1470-1472, 1994.
22. Nanashima A, Yamaguchi H, Sawai T, Yamaguchi E, Kidogawa H, Matsuo S, Yasutake T, Tsuji T, Jibiki M, Nakagoe T and Ayabe H: Prognostic factors in hepatic metastases of colorectal carcinoma: immunohistochemical analysis of tumor biological factors. Dig Dis Sci 46: 1623-1628, 2001.
23. Zlobec I, Günthert U, Tornillo L, Iezzi G, Baumhoer D, Terracciano L and Lugli A: Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer. Histopathology 55: 564-575, 2009.
24. Wada T, Ishimoto T, Seishima R, Tsuchihashi K, Yoshikawa M, Oshima H, Oshima M, Masuko T, Wright NA, Furuhashi S, Hirashima K, Baba H, Kitagawa Y, Saya H and Nagano O: Functional role of CD44v-xCT system in thedevelopment of spasmolytic polypeptide-expressing metaplasia. Cancer Sci 104: 1323-1329, 2013.
25. Nabeyama A, Kurita A, Asano K, Miyake Y, Yasuda T, Miura I, Nishitai G, Arakawa S, Shimizu S, Wakana S, Yoshida H and Tanaka M: xCT deficiency accelerates chemically induced tumorigenesis. Proc Natl Acad Sci 107: 6436-6441, 2010.
26. Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, Yoshida GJ, Wada T, Masuko T, Mogushi K, Tanaka H, Osawa T, Kanki Y, Minami T, Aburatani H, Ohmura M, Kubo A, Suematsu M, Takahashi K, Saya H and Nagano O: Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun 3: 883: 1-9, 2012.
27. Chen RS, Song YM, Zhou ZY, Tong T, Li Y, Fu M, Guo XL, Dong LJ, He X, Qiao HX, Zhan QM and Li W: Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/b-catenin pathway. Oncogene 28: 599-609, 2009.
28. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F and de Gramont A: Improved overall survival with oxaliplatin, fluorouracil,and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncology 27: 3109-3116, 2009.